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CASE PRESENTATION
A 59-year-old Hispanic male with a history of type II
diabetes mellitus, hypertension, and end-stage renal
disease (on hemodialysis for 2 years) was called in for a
kidney transplant. He was in his usual health, having
received dialysis earlier in the day. The kidney donor
was from an expanded criteria pool and was a
59-year-old Caucasian male with diabetes mellitus who
expired following a cerebrovascular accident. He had a
terminal creatinine of 1.3 mg/dl (114.92mmol/l (nl range
0.6–1.2 mg/dl/53.04–106.08mmol/l)) and no evidence of
proteinuria. A donor renal biopsy revealed 10–15% tubular
atrophy and interstitial fibrosis. There was a six-antigen
mismatch, and cold ischemia time was 31 h. The final
complement-dependent cytotoxic and flow cytometry
crossmatch were negative. Renal transplantation was
performed.
At the time of transplantation, the patient received
alemtuzumab (Campath; anti-CD52 monoclonal antibody)
and solumedrol as induction therapy. The patient had an
intra-operative episode of hypotension that resolved with
a 500 ml bolus of normal saline and 250 ml of 6%
hetastarch lactate electrolyte solution. At the completion
of surgery, the patient was stable and was extubated and
moved to recovery. On physical exam, he was normoten-
sive with normal sinus rhythm, clear lungs, good dorsalis
pedis pulses, and no peripheral edema. He had been
anuric before surgery, but had made 10 ml of urine during
the first hour.
One hour after surgery, the patient’s systolic blood
pressure dropped to 80 mmHg. In an effort to sustain his
blood pressure, he was given multiple boluses of normal
saline, lactate Ringers solution, and an additional 1 l of 6%
hetastarch. He was eventually started on vasopressin and
moved to the Intensive Care Unit. His hematocrit
remained stable, but his potassium was elevated at
6.0 mM/l. Continuous renal replacement therapy was
initiated. Renal ultrasound initially was unable to demon-
strate arterial or venous blood flow. After 4 h, his blood
pressure improved and he was weaned off vasopressin. A
repeat ultrasound 24 h later showed restoration of arterial
and venous blood flow. Maintenance immunosuppression
was started on post-operative day 1 and included
tacrolimus and mycophenolate mofetil. His tacrolimus
trough level ranged between 9 and 13 ng/ml. The patient
remained oliguric and hemodialysis-dependent during the
first week. Due to delayed graft function and a creatinine
of 6.2 mg/dl (548.08mmol/l), renal allograft biopsy was
performed on post-operative day 8.
RENAL BIOPSY FINDINGS
Sampling for light microscopy consisted of two cores of renal
cortex and medulla. There were 14 glomeruli present, one of
which was globally sclerotic. Glomeruli appeared enlarged
and exhibited a mild-to-moderate global increase in
mesangial matrix, which predominantly formed nodules.
There was mild thickening of the glomerular basement
membrane. Proximal tubular epithelial cells were markedly
swollen with abundant clear cytoplasmic vacuoles, consistent
with a pattern of osmotic nephrosis (Figure 1). Additional
tubular degenerative changes included luminal ectasia,
cytoplasmic simplification, and focal apoptotic bodies. There
was minimal tubular atrophy and interstitial fibrosis invol-
ving only 5% of the cortex sampled. There was no significant
interstitial inflammation or tubulitis. Vessels exhibited
moderate arteriosclerosis and arteriolosclerosis with hyali-
nosis. There was no evidence of endovasculitis.
Immunofluorescence revealed low intensity (þ /) linear
positivity for immunoglobulin G (IgG) and albumin in
glomerular and tubular basement membranes, as is com-
monly encountered in diabetic glomerulosclerosis. There was
no evidence of granular positivity for IgG. Staining for IgM,
IgA, C3, C1, fibrinogen, and kappa and lambda light chains
was negative in glomeruli. The absence of C4d positivity
in peritubular capillaries provided evidence against acute
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antibody-mediated rejection. Electron microscopy was not
performed.
Pathologic diagnosis
1. Tubular degenerative changes with osmotic nephrosis.
2. Nodular diabetic glomerulosclerosis, moderate (donor
transmitted).
3. Arteriosclerosis and arteriolosclerosis with hyalinosis,
moderate (donor transmitted).
CLINICAL FOLLOW-UP
Following the biopsy, the patient’s urine output improved
and the creatinine began to decline. At the time of discharge,
the patient’s creatinine was 3.7 mg/dl (327.08 mmol/l) and his
medications included tacrolimus, mycophenolate mofetil,
valgancyclovir, trimethoprim sulfamethoxazole SS, nystatin
oral solution, furosemide, rosiglitazone, insulin, and meto-
prolol. The patient’s creatinine did not decline further and
over the subsequent 5 months ranged between 4.0 and
5.0 mg/dl (353.6 and 442 mmol/l), despite discontinuation of
treatment with tacrolimus. At 5-month post-transplantation,
the patient’s creatinine is 4.8 mg/dl (424.32 mmol/l). During
the intercurrent time period, the patient has had three
additional renal allograft biopsies, each of which revealed
persistent findings of osmotic nephrosis. On the most recent
allograft biopsy, performed 4 months post-transplantation,
the degree of tubular atrophy and interstitial fibrosis had
increased to 30%.
DISCUSSION
Osmotic nephrosis is a distinct pattern of acute tubular
injury observed following parenteral infusion of hyperoncotic
solutions. Cellular injury begins with the uptake of non-
metabolizable molecules by pinocytosis into proximal tubule
cells.1 The molecules create an oncotic gradient, leading to
the accumulation of intra-cellular water, severe cytoplasmic
swelling and vacuolization, and disruption of cellular
integrity. Osmotic nephrosis is associated with acute renal
failure and a clinical presentation similar to that of acute
tubular necrosis. Only with renal biopsy can the distinctive
pattern of osmotic nephrosis be recognized.
Osmotic nephrosis was first described in 1940 when
patients with increased intracranial pressure were treated
with intravenous solutions of hypertonic sucrose.2 The
authors recognized that the tubular vacuolization was only
seen in patients who received hypertonic sucrose and
resembled the tubular changes described in dogs receiving
daily infusions of sucrose.3 A subsequent study confirmed the
relationship between hypertonic sucrose and osmotic ne-
phrosis, showed that this lesion could also be induced in
rabbits, and emphasized the role of dehydration.4 Osmotic
nephrosis was initially referred to as sucrose nephropathy.
Additional experience has shown that it can be seen with
multiple additional therapeutic agents1,5 (Table 1).
Osmotic nephrosis is commonly encountered in renal
allograft biopsies. This is because intravenous Ig is used
frequently for the treatment of acute antibody-mediated
rejection, and less commonly for viral infection. Among the
intravenous Ig formulations, preparations that use sucrose as
the stabilizing agent are most commonly associated with
osmotic nephrosis, although this finding may also occur
with maltose-containing preparations.6 Osmotic nephrosis is
also often seen in post-reperfusion allograft biopsies owing to
the common use of mannitol before transplantation in the
donor or intra-operatively in the recipient. In the case
reported herein, there was no history of intravenous Ig or
mannitol use. In contrast, the patient had received hydroxy-
ethyl starch (HES).
HES is a volume expander used in perioperative and
intensive care settings. HES increases plasma refilling by
increasing oncotic pressure in the intravascular space and has
the advantage of a more long-lasting effect than crystalloid
and a lower cost than albumin. HES is derived from
amylopectin, a highly branched polymer of glucose and the
primary storage polysaccharide found in plants. HES is
created by the addition of hydroxyethyl subgroups to
amylopectin. Its counterpart in animals is glycogen, which
has a similar composition but branches at each 8–12 glucose
Figure 1 | Osmotic nephrosis is characterized by marked swelling
of proximal tubular epithelia that contain abundant clear
cytoplasmic vacuoles. Compared to the isometric tubular vacuoli-
zation seen with calcineurin inhibitor toxicity, the cells appear more
swollen and the vacuoles are larger, more abundant, and more
diffusely distributed. (Hematoxylin and eosin original magnification,
 400.)
Table 1 | Therapeutic agents associated with osmotic
nephrosis
1. Sucrose
2. Mannitol
3. Intravenous immunoglobulin
4. Radiocontrast agents
5. Dextran
6. Hydroxyethyl starch
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units, compared to branching at each 24–30 subunits in
amylopectin.
Multiple HES solutions are available and differ in their
molecular weight and molar substitution.7 The molar
substitution is of particular importance, in that a higher
number is associated with a slower rate of hydrolysis by
serum alpha-amylase and therefore a longer duration of
action. Metabolites of HES are excreted in the urine.
Although HES preparations have the benefit of low cost,
they have the potential for serious adverse reactions,
including kidney failure, hemorrhage, refractory pruritis,
and anaphylactoid reactions.8 The hemorrhagic effect of HES
derives from its ability to deplete plasma concentrations of
factor VIII and von Willebrand factor and to impair platelet
reactivity.9 Thus, HES should be used with great caution in
patients with overt bleeding, von Willebrand disease,
hemophilia, and other coagulopathies.9
In 1993, Legendre et al.10 described the new occurrence of
osmotic nephrosis-like lesions in 80% of renal transplant
recipients at a large center in France and noted that this
occurrence coincided with the new practice of giving HES to
brainstem-dead patients before organ procurement. In this
retrospective study, no deleterious effect on delayed graft
function was detected, and it was noted that the findings of
osmotic nephrosis persisted in some cases for at least 3
months. A subsequent prospective analysis from the same
center was able to show a significant negative impact of HES
use on graft function.11 Brain-dead donors were adminis-
tered either HES–gelatin or gelatin alone for volume
expansion. During the first 8 days post-transplantation, nine
of 27 (33%) patients in the HES group required hemodia-
lysis, as compared to only one of 20 (5%) in the gelatin group
(P¼ 0.029). At day 10 post-transplantation, the mean serum
creatinine was 145 mmol/l in the gelatin group, compared to
312 mmol/l in the HES group (P¼ 0.009).11 Three patients in
the HES group underwent renal biopsy, all of whom had
findings of osmotic nephrosis. While long-term follow-up
was not provided, this study clearly demonstrated a
significant negative short-term effect of HES on graft
function.
HES nephrotoxicity is also seen outside of the renal
transplant setting. A multicenter prospective trial compared
HES and gelatin in 129 adult patients with severe sepsis or
septic shock. Patients who received HES had a higher
frequency of acute renal failure (P¼ 0.028), oliguria
(P¼ 0.025), and a higher peak serum creatinine
(P¼ 0.04).12 In multivariate analysis, the use of HES was
shown to be an independent risk factor for acute renal failure,
with an odds ratio of 2.57 (P¼ 0.026).12 There have also been
individual case reports of acute renal failure and biopsy
findings of osmotic nephrosis following HES administra-
tion.13,14
Other studies have failed to demonstrate significant
nephrotoxicity associated with HES. A prospective study on
40 patients over the age of 70 years undergoing cardiac
surgery with cardiopulmonary bypass compared low mole-
cular weight HES to gelatin. In both groups, creatinine
clearance were similar, as was the degree of elevation of
multiple urinary markers of tubular injury, including
N-acetyl-beta-D-glucosamidase, alpha-1-microglobulin, and
glutathione transferase.15 A large, retrospective study on 3124
patients who underwent cardiac surgery similarly revealed no
difference in post-operative renal function between patients
treated with HES or gelatin.16
While the acute effects of HES exposure on renal function
are partially understood, less is known about the long-term
impact. In the case reported herein, renal failure and the
pathologic findings of osmotic nephrosis persisted for at least
4 months. A recent study looked at renal biopsy findings in
patients with chronic renal insufficiency who had undergone
orthotopic liver transplantation.17 Findings of osmotic
nephrosis could still be identified up to 10 years following
HES administration, were associated with a greater degree of
tubulointerstitial scarring, and were attributed to the use
of HES. Thus, the authors raised the possibility that this
study represents the first documentation of chronic HES
nephrotoxicity.17
HES is one of a number of therapeutic agents that may
cause acute renal failure with renal biopsy findings of osmotic
nephrosis (Table 1). The risk of HES nephrotoxicity appears
to be greatest in the setting of underlying renal disease. In the
case reported herein, HES was used in a renal transplant
recipient with significant donor-transmitted diabetic glomer-
ulosclerosis and vascular disease, prolonged cold ischemia
time, and intra-operative and post-operative hypotension. In
this setting of pre-existing compromised renal function,
acute renal failure owing to osmotic nephrosis occurred and
has persisted for at least 5 months. Although HES should be
used judiciously in all patients, even greater caution should
be exercised in renal transplant recipients during the peri-
operative period. Due to the national shortage of organs for
transplantation and the increased use of expanded criteria
donors, the potential for acute and chronic renal failure
following treatment with HES is likely to increase.
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